Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 Apr 4:30:101050.
doi: 10.1016/j.rmcr.2020.101050. eCollection 2020.

Rapid onset of effect of benralizumab on respiratory symptoms in a patient with eosinophilic granulomatosis with polyangiitis

Angelo Coppola  1 , Krisstopher Richard Flores  1 , Francesca De Filippis  1
Affiliations
Case Reports

Rapid onset of effect of benralizumab on respiratory symptoms in a patient with eosinophilic granulomatosis with polyangiitis

Angelo Coppola et al. Respir Med Case Rep. .

Abstract

A 63 years - old woman affected by severe eosinophilic asthma associated with EGPA presented refractory respiratory symptoms, resistant to high dose oral corticosteroid treatment. A significant hyper-eosinophilia was present at the blood test, and the ACT score was steadily low, despite the maximal dose of inhalation therapy. The CT chest scan showed a persistent diffuse bronchial wall thickening, pulmonary infiltration and paranasal sinusitis. We report here the rapid onset of effect of benralizumab 30 mg in a monthly subcutaneous injection in reducing patient's symptom, inducing regression of CT scan abnormalities, determining a steroid sparing effect and improving lung function tests after 3 months of therapy. A fast and stable reduction of peripheral eosinophilia associated with an increase in ACT score were also documented after the first dose of benralizumab.

Keywords: Anti IL-5Ra; Benralizumab; Churg; EGPA; Eosinophils; Strauss syndrome.

PubMed Disclaimer

Conflict of interest statement

“I declare on behalf of my co-authors and myself that we do not have any conflict of interest to declare”.

Figures

Fig. 1
Fig. 1
A) Computed Tomography shows bilateral sinusitis (A–B) and diffuse bronchial wall thickening associated with pulmonary infiltration (C). The CT scan after 3 months of treatment with benralizumab showed a quite completely regression of bronchial wall thickening and pulmonary infiltration (D).
See this image and copyright information in PMC

References

    1. Jennette J.C., Falk R.J., Bacon P.A. Revised international Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum. 2012;65:1–11. 2013. - PubMed
    1. Khoury P., Grayson P.C., Klion A.D. Eosinophils in vasculitis: characteristics and roles in pathogenesis. Nat. Rev. Rheumatol. 2014;10:474–483. - PMC - PubMed
    1. Wechsler M.E., Akuthota P., Jayne D., Khoury P., Klion A., Langford C.A., Merkel P.A., Moosig F., Specks U., Cid M.C., Luqmani R., Brown J., Mallett S., Philipson R., Yancey S.W., Steinfeld J., Weller P.F., Gleich G.J., Egpa Mepolizumab Study Team Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N. Engl. J. Med. 2017 May 18;376(20):1921–1932. - PMC - PubMed
    1. Faverio P., Bonaiti G., Bini F., Vaghi A., Pesci A. Mepolizumab as the first targeted treatment for eosinophilic granulomatosis with polyangiitis: a review of current evidence and potential place in therapy. Therapeut. Clin. Risk Manag. 2018 Dec 7;14:2385–2396. eCollection 2018. Review. PMID: 3057396. - PMC - PubMed
    1. Rosenwasser L.J., Rothenberg M.E. IL-5 pathway inhibition in the treatment of asthma and Churg-Strauss syndrome. J. Allergy Clin. Immunol. 2010 Jun;125(6):1245–1246. - PubMed

Publication types

LinkOut - more resources